These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36544189)

  • 1. Scale-up of the DMPA-SC in Nigeria: Why policy matters.
    Akinyemi O; Danfakha N; Adefalu A; Easley E; Afolabi K; Latunji O
    BMC Womens Health; 2022 Dec; 22(1):535. PubMed ID: 36544189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introducing the subcutaneous depot medroxyprogesterone acetate injectable contraceptive via social marketing: lessons learned from Nigeria's private sector.
    Liu J; Schatzkin E; Omoluabi E; Fajemisin M; Onuoha C; Erinfolami T; Ayodeji K; Ogunmola S; Shen J; Diamond-Smith N; Sieverding M
    Contraception; 2018 Nov; 98(5):438-448. PubMed ID: 30071196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review.
    Aderoba AK; Steyn PS; Kiarie JN
    Syst Rev; 2023 Jul; 12(1):114. PubMed ID: 37403147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries.
    Stout A; Wood S; Barigye G; Kaboré A; Siddo D; Ndione I
    Glob Health Sci Pract; 2018 Mar; 6(1):55-72. PubMed ID: 29602866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda.
    Odwe G; Gray K; Kyarimpa A; Obare F; Nagendi G
    Glob Health Sci Pract; 2018 Dec; 6(4):711-722. PubMed ID: 30429201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Men can take part": examining men's role in supporting self-injectable contraception in southern Malawi, a qualitative exploration.
    Ruderman LW; Packer C; Zingani A; Moses P; Burke HM
    Reprod Health; 2022 Aug; 19(1):174. PubMed ID: 35945601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of job aids on knowledge retention among Patent and Proprietary Medicine Vendors trained to administer injectable contraceptives: longitudinal results from implementation science in Nigeria.
    Chace Dwyer S; Jain A; Ishaku SM; Okunade FT; Uzomba C; Adebayo A; Tobey E
    BMC Public Health; 2019 Oct; 19(1):1362. PubMed ID: 31651273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing a global monitoring system for pilot introduction of a new contraceptive technology, subcutaneous DMPA (DMPA-SC).
    Stout A; Wood S; Namagembe A; Kaboré A; Siddo D; Ndione I
    Eval Program Plann; 2018 Jun; 68():185-193. PubMed ID: 29609057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing the Introduction and Scale Up of Self-Administered Injectable Contraception (DMPA-SC) in Health Systems (the EASIER Project): Protocol for Embedded Implementation Research.
    Baynes C; Steyn PS; Sherr K; Kiarie J
    JMIR Res Protoc; 2023 Aug; 12():e44222. PubMed ID: 37610819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects.
    Liu J; Shen J; Diamond-Smith N
    Contraception; 2018 Nov; 98(5):430-437. PubMed ID: 29733817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results.
    Okegbe T; Affo J; Djihoun F; Zannou A; Hounyo O; Ahounou G; Bangbola KA; Harris N
    Glob Health Sci Pract; 2019 Jun; 7(2):228-239. PubMed ID: 31171559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Client and provider experiences with self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Malawi.
    Burke HM; Packer C; Buluzi M; Healy E; Ngwira B
    Contraception; 2018 Nov; 98(5):405-410. PubMed ID: 29706227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
    Upadhyay UD; Zlidar VM; Foster DG
    Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuation of subcutaneous or intramuscular injectable contraception when administered by facility-based and community health workers: findings from a prospective cohort study in Burkina Faso and Uganda.
    MacLachlan E; Atuyambe LM; Millogo T; Guiella G; Yaro S; Kasasa S; Bukenya J; Nyabigambo A; Mubiru F; Tumusiime J; Onadja Y; Zan LM; Goeum/Sanon C; Kouanda S; Namagembe A
    Contraception; 2018 Nov; 98(5):423-429. PubMed ID: 30125558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of administering injectable contraceptives through health workers and self-injection: evidence from Burkina Faso, Uganda, and Senegal.
    Di Giorgio L; Mvundura M; Tumusiime J; Namagembe A; Ba A; Belemsaga-Yugbare D; Morozoff C; Brouwer E; Ndour M; Drake JK
    Contraception; 2018 Nov; 98(5):389-395. PubMed ID: 29859148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Service Delivery Considerations for Introducing New Injectable Contraceptives Lasting 4 and 6 Months in Nigeria and Uganda: A Qualitative Study.
    Callahan RL; Burke HM; Lawton A; OlaOlorun FM; Mubiru F; Anyasi H; Wong CM; Bidashimwa D; Velarde M; Ruderman LW
    Glob Health Sci Pract; 2023 Dec; 11(6):. PubMed ID: 38135518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-injected contraceptives: does the investment reflect women's preferences?
    Wood SN; Magalona S; Zimmerman LA; OlaOlorun F; Omoluabi E; Akilimali P; Guiella G; Gichangi P; Anglewicz P
    BMJ Glob Health; 2022 Jul; 7(7):. PubMed ID: 35835480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC).
    Kohn JE; Berlan ED; Tang JH; Beasley A
    Contraception; 2022 Aug; 112():11-13. PubMed ID: 35378085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of triggers, ideation and motivational factors of contraceptive utilization among women and gate-keepers in Nigeria: a scoping study on the resilient and accelerated scale up of DMPA-SC in Nigeria (RASUDIN).
    Osinowo K; Ekholuenetale M; Ojomo O; Hassan A; Ladipo OA
    Contracept Reprod Med; 2020 Dec; 5(1):38. PubMed ID: 33292709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda.
    Cover J; Namagembe A; Tumusiime J; Nsangi D; Lim J; Nakiganda-Busiku D
    Contraception; 2018 Nov; 98(5):383-388. PubMed ID: 29654751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.